Subsequently, we showed that women with advanced non-small cell lung cancer (NSCLC) experienced impressive larger survival benefit than men, from the combination of chemotherapy with an anti-PD-1 or anti-PD-L1.5 This evidence concerns the gene CD274 and non-small cell lung carcinoma.